Synchron receives FDA approval to begin early feasibility study of their endovascular, brain‐computer interface device

Stentrode by Synchron is an endovascularly implanted brain computer interface platform that can relay the activities from the motor cortices of paralyzed patients, potentially offering a relatively noninvasive option for more than five million people in the United States alone.